Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/26/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Nicholas P. Plotnikoff

Wrong Dr. Nicholas P. Plotnikoff?

Emeritus Professor of Pharmacolog...

Phone: (217) ***-****  HQ Phone
Local Address:  Chicago , Illinois , United States
University of Illinois
1101 West Peabody Drive
Urbana , Illinois 61801
United States

Company Description: The University of Illinois at Urbana–Champaign (U of I, University of Illinois, UIUC, or simply Illinois) is a public research-intensive university in the U.S....   more

Employment History


  • Ph.D. , Pharmacology
27 Total References
Web References
LDN: The Latest News, 26 Dec 2014 [cached]
Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, recently announced that his company has acquired all of Dr. Bernard Bihari's use-patents for low dose naltrexone.
Dr. Plotnikoff, quoted on the TNI BioTech website, said:
Dr. Plotnikoff, Emeritus Professor of Pharmacology and Psycho­neuro­immuno­logy, College of Pharmacy and College of Medicine, at the University of Illinois in Chicago, holds a PhD in Pharmacology. Prior to TNI, Dr. Plotnikoff helped direct research for Abbott Labs.
Following welcoming remarks from Jeffrey Abrams, MD, Chief of the Clinical Investigations Branch of the NCI, speakers included David Gluck, MD (Introductory Overview); Jill Smith, MD (Clinical Experience with LDN in Crohn's Disease; Opioid Growth Factor in Pancreatic Cancer); John Hong, PhD (Anti-Inflammatory and Neuroprotective Effects of Naltrexone and Its Analogs); Nicholas Plotnikoff, PhD (Overview of Metenkephalin Actions in HIV Infections); Burton M. Berkson, MD, PhD (Personal Experiences with LDN for Various Cancers); Maira Gironi, MD, PhD and Filippo M. Boneschi, MD, PhD (Ongoing Pilot Study of LDN in MS: Preliminary Findings).
Invitees thus far include I. Zagon, PhD; Jill P. Smith, MD; John Hong, PhD; and Nicholas Plotnikoff, PhD; as well as physician practitioners with experiences in LDN treatment.
News: Skystar Bio-Pharmaceutical Signs Agreement With TNI-Penta for Research and Development of New Veterinary Drugs. Genetic Engineering News - Biotechnology from Bench to Business, 24 Jan 2007 [cached]
TNI-Penta's executive team, lead by Dr. Nicholas Plotnikoff, met with Skystar's executive management and top research team in Xi'an, China in early January and signed a three-year agreement whereby TNI-Penta will provide MEK Active Pharmaceutical Ingredients (API), requisite technology, intellectual property rights, and technical and consulting services to Skystar to help in performing tests in a controlled environment to evaluate the safety, duration of immunity, minimum effective dosage and protective efficacy of the newly developed drugs containing MEK API.Once the products have successfully passed all testing stages, Skystar will file for government approval for mass production and sale throughout China.TNI-Penta will receive an average of 9% of the gross revenues realized from sale of any new product developed through this joint venture.
Dr. Nicholas Plotnikoff, Chairman and CEO of TNI-Penta, commented, "Both Dr. Huang, President of Penta Biotech, and I are very excited and eagerly awaiting the results of the initial testing phase of the potential applications of our cytokine met-enkephalin to a variety of veterinary pharmaceutical uses.
With Dr. Plotnikoff and his team's input and assistance, we are seeking to revolutionize our industry by developing new and highly effective products using methods and technologies never before used in this area."
TNI-Penta is a joint venture between TNI Pharmaceuticals, Inc. and Penta Biotech, Inc. and is led by renowned scientist Dr. Nicholas Plotnikoff.
TNI-Penta's Chairman and CEO, Dr. Nicholas Plotnikoff's principal research interests are in the areas of psychoneuroimmunology with special emphasis on stress hormones and cytokines (enkephalins-endorphins).His current research has been focused on the clinical effects of methionine enkaphalin in the treatment of cancer and AIDS patients.
Board of Directors, 26 Oct 2014 [cached]
Dr. Nicholas Plotnikoff, Non-Executive Chairman ?
Dr. Plotnikoff has a Ph.D. in Pharmacology, with over 20 years in the pharmaceutical industry, working in Pharmacology, Toxicology, and Clinical Research. Dr. Plotnikoff was a Professor of Pharmacology at the University of Illinois Medical Center in Chicago. Dr. Plotnikoff played a pioneering role in investigations of the immunological effects of MENK. He also successfully managed the project teams that developed the NDAs on Traxene (Valium-like tranquilizer) and Cylert (non-amphetamine psychostimulant).
In basic research he was the first to identify the central nervous system effects of hypothalamic releasing factors (brain hormones), resulting in their clinical development for treatment of depression and Parkinson's disease. Dr. Plotnikoff co-authored 25 publications with Dr. Andrew Schally covering basic research in the field of depression and Parkinson's disease.
Dr. Plotnikoff held a number of international patents for the use of MENK in HIV/AIDS and cancer.
NEWS NOTES, 7 Dec 2007 [cached]
The funding was announced on March 16 by Dr. Nicholas P. Plotnikoff, chairman and founder of TNI, which holds patents on the use of MEK as a possible treatment in AIDS and cancer.
TNI: About Us, 5 Feb 2010 [cached]
Nicholas Peter Plotnikoff, President & Director With more than 25 years of experience in the healthcare sciences industry, the guiding genius behind TNI Pharmaceuticals, Inc. is Dr. Nicholas Plotnikoff, who is known worldwide as the discoverer of the action of hypothalamic releasing hormones on the central nervous system and also as a pioneer for his work on encephalin and endorphins (produced by the immune system). Dr. Plotnikoff secures 28 patents. Prior to founding TNI, Dr. Plotnikoff directed research for Abbott Labs that developed Tranexene, a valium-like tranquilizer. He has also lead the research, development, and treatment applications for several other drugs including Cylert (a non amphetamine stimulant for hyperactive children) and Depekene (an anti-epileptic agent).
Other People with the name "Plotnikoff":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.